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Objectives: To evaluate the prognostic role of venous tumor thrombus consistency in
patients with renal cell carcinoma.
Methods: A retrospective evaluation of the data of patients with renal cell carcinoma and
a tumor thrombosis submitted to surgery from 2000 to 2013 was carried out. Histological
slides were revised by two uropathologists, blinded of the clinical outcome, to assess ve-
nous tumor thrombus consistency classified as solid venous tumor thrombus consistency
or friable venous tumor thrombus consistency. The statistical correlation between venous
tumor thrombus consistency and other adverse features was assessed. Then the predictive
ability of an integrated prognostic model, generated by Cox regression and random survival
forest, was evaluated, with and without the inclusion of venous tumor thrombus
consistency, by integrated Brier score, dynamic receiver operating characteristic curves,
integrated discrimination improvement index and category-less net reclassification index.
Results: The data of 147 patients were analyzed, 79 with a solid venous tumor thrombus
consistency and 68 with a friable venous tumor thrombus consistency, followed for a me-
dian period of 40.5months. Venous tumor thrombus consistency was assessed with a high
interobserver agreement (145/147 cases). The presence of a friable venous tumor thrombus
consistency was associated with some adverse prognostic factors (symptoms, lymphnodal
and distant metastasis, larger tumor diameter, higher cephalad thrombosis level, necrosis,
microvascular invasion) and to a worse cancer-specific and overall survival at univariate anal-
ysis. However, venous tumor thrombus consistency was not predictive of survival, and did
not improve the performance of a multivariable model that included a set of informative
predictors.
Conclusion: Venous tumor thrombus consistency does not seem to have an independent
prognostic role in patients with renal cell carcinoma.
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Introduction
The prognosis of RCC with tumor thrombosis is quite heterogeneous and not always predictable.
Indeed, even if there are various prognostic factors generally effective for RCC, such as tumor
size, grading, histological subtype, presence of sarcomatoid features, invasion of perirenal tissues
and nodal or distant metastasis, as well as in the cases with a thrombosis, very few factors specific
to these patients are available and their role is still controversial, as it is for the cranial level
reached by the thrombus.1–6
Surgery in this setting is highly invasive and can be curative only in a subset of patients, so that
a more precise prognostic prediction might be useful for surgical selection, indication to neoad-
juvant or adjuvant therapy and follow up.
Recently, VTTC, defined as solid or friable, has been suggested as a prognostic factor by
Bertini et al.; in that study, VTTC was independently related to survival, both OS and CSS,
and was shown to slightly improve the predictive performances of a risk model.7 At present,
the only study that tried to validate the prognostic role of VTTC in an external setting achieved
rather conflicting results, as VTTC was shown to be significantly associated only to OS and
solely in patients without metastasis at diagnosis.8
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Therefore, the prognostic role of VTTC still needs to be
ascertained. The aim of the present study was to investigate
if and to what extent it is an independent predictor of CSS
and OS.
Methods
The data of all the patients submitted to surgery for RCC
at Spedali Civili Hospital, Brescia, Italy, are stored in a
prospectively-maintained database, which includes more than
2300 consecutive patients. After surgery, all the patients are
followed according to a tailored protocol at a dedicated office.9
This database was used to retrieve the information of patients
with RCC and tumor thrombosis observed in the period from
2000 to 2013. In lieu of formal ethics committee approval, the
principles of the Helsinki declaration were followed.
The histological specimens were independently revised by
two uropathologists. One was skilled, with more than 20 years
of experience (RT), and the second was a novice, attending
the last year of residency (MY); both were blinded to the clini-
cal outcome of the patients. The revision assessed tumor size,
histological subtype, Fuhrman grading, invasion of perirenal
tissues, microvascular invasion, coagulative tumor necrosis
and sarcomatoid de-differentiation, all defined according to
the recommendations from the last consensus conference of
the International Society of Urological Pathology.10,11
Following the definition used by Bertini et al., VTTC was de-
fined as solid when the thrombus appeared compact and cohe-
sive, with a rounded linear profile and an endothelial lining
simulating a pseudocapsule in more than 90% of its surface,
otherwise it was defined as friable if it was incoherent, irregular,
with necrotic areas and a fragmented aspect.7 Furthermore, the
extent of the friable pattern was defined limited if present in less
than 50% of the specimen, and extensive when more repre-
sented (Fig. 1).
Statistical analysis
OS was calculated from the date of surgery to the date of death
from any cause or last follow up; CSS was calculated from the
date of surgery to the date of death from cancer-related cause or
last follow up.
To investigate the added value of VTTC for the prediction of
OS and CSS, the statistical analysis compared the predictive
performances of the multivariable model including VTTC plus
a set of predictive covariates (Model1) to the same model with-
out VTTC (Model0). The models used in the aforementioned
analysis were the traditional Cox regression and RSF, a novel
non-parametric machine learning method that is less prone to
overfit, handles non-linearity, collinearity and interactions be-
tween predictors.12 The selection of the predictive covariates
for OS and CSS were carried out by means of the stepwise
backward method (for Cox regression) and the method of
minimal-depth variable importance (for RSF).13
The predictive power of Model0 and Model1 models was
then estimated and compared by three classes of statistical mea-
sures for censored data:
1 Prediction error curves and cumulative prediction error (i.e.
Integrated Brier Score) using cross-validation and bootstrap
methods; the null hypothesis of absence of an added predic-
tive value of VTTC was tested by the van de Wiel test.14
2 Cumulative/dynamic time-dependent ROC curves, a general-
ization of the ROC methodology in the presence of censored
data; the significance of differences between area under the
ROC curves was investigated using the test proposed by
Blanche et al.15
3 As ROC curves might not be sensitive enough to capture
incremental improvements from a given predictor, some
reclassification measures were evaluated: IDI, NRI16,17 and
median improvement in risk score.
Kaplan–Meier survival curves adjusted for potential con-
founders and the associated log–rank test were estimated using
inverse probability weights.18
Statistical significance was defined as a P-value <0.05.
Statistical analyses were carried out using R version 3.1.019
with pec, randomForestSRC, timeROC, survIDINRI and ipw
packages.
Results
During the period of the study, 1238 patients were submitted to
surgery for a renal tumor; among them, 189 had a RCC with a
thrombosis, and for 147 (77.8%) the pathological specimens
were available.
A sVTTC was identified in 79 cases (53.7%), a fVTTC in 68
cases (46.3%), limited in 26, extensive in 42. The diagnosis
between pathologists was concordant in 145 out of 147 cases
(98.6%) relative to the discrimination between sVTTC and
fVTTC, and in 65 out of 67 (97.0%) for the discrimination
between limited and extensive fVTTC.
Table 1 compares the characteristics of fVTTC with sVTTC
patients. The distribution of demographic features and comor-
bidities did not differ significantly, whereas several clinical
and pathological features, indicative of more advanced stage
and higher aggressiveness, were more common in patients with
a fVTTC.
The patients were followed for a median time of 40.5months
(range 1–215months, interquartile range 14–78months). At
last follow up, 53 patients (35.1%) were alive without evidence
Fig. 1 Microscopic view of hematoxylin–eosin
of (a) solid, (b) limited friable and (c) extensive
friable tumor thrombus (the arrow indicates
the venous wall).
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of disease after a median time of 42.5months from surgery, 36
(24.5%) were alive with a progression after a median time of
25.3months, 52 (36.4%) died as a result of RCC at a median
time of 25.5months and six (4.1%) died from causes different
from RCC at a median time of 23.0months.
Table 2 reports the explanatory variables identified by two
variable selection methods in the overall cohort and in the se-
lected cohort of patients without metastasis at diagnosis. Ad-
justed HR for the selected covariates (age, thrombosis level,
pathological grade, microvascular invasion, perirenal tissues in-
vasion, Charlson Comorbidity Index and distant metastasis)
were estimated for OS and CSS using a multivariable Cox
model. It can be noted that VTTC did not show a statistically
significant HR in all the analyses carried out (Table 2). Unad-
justed HR are reported in Table S1.
In the overall cohort, the 5-year CSS (adjusted for other
predictors) in patients with sVTTC and fVTTC was 61.0%
(95% CI 49.9–74.7%) and 60.6% (95% CI 48.4–75.8%),
respectively; the adjusted 5-year CSS for M0 patients with
sVTTC and fVTTC was 69.0% (95% CI 57.7–82.5%) and
66.7% (95% CI 53.0–83.9%), respectively (Table 2). The
comparison of the sVTTC- and fVTTC-adjusted survival
Table 1 Patient characteristics and descriptive statistics in the overall study cohort and by VTTC
All patients (n = 147) Friable VTTC (n = 68) Solid VTTC (n = 79) P
Median age, years (range) 66.0 (35.5–85.0) 65.7 (37.0–79.3) 68.2 (35.5–85.0) 0.383
Sex, n (%) 0.733
Male 92/147 (62.6) 44/68 (64.7) 48/79 (60.8)
Female 55/147 (37.4) 24/68 (35.3) 31/79 (39.2)
Charlson Comorbidity Index, n (%) 0.616
0 93/147 (63.3) 45/68 (66.2) 48/79 (60.8)
1–2 42/147 (28.6) 19/68 (27.9) 23/79 (29.1)
≥3 12/147 (8.1) 4/68 (5.9) 8/79 (10.1)
Symptoms, n (%) 0.013
Absent 46/146 (31.5) 13/67 (19.4) 33/79 (41.8)
Local 67/146 (45.9) 35/67 (52.2) 32/79 (40.5)
Systemic 33/146 (22.6) 19/67 (28.4) 14/79 (17.7)
Side, n (%) 0.333
Right 75/147 (51.0) 38/68 (55.9) 37/79 (46.8)
Left 64/147 (43.5) 28/68 (41.2) 36/79 (45.6)
Bilateral 8/147 (5.5) 2/68 (2.9) 6/79 (7.6)
Hystological subtype, n (%) <0.001
Clear cell 130/147 (88.4) 53/68 (77.9) 77/79 (97.5)
Others 17/147 (11.6) 15/68 (22.1) 2/79 (2.5)
Median tumor diameter, cm (range) 8.0 (3.2–21.0) 9.0 (3.2–19.0) 8.0 (3.5–21.0) 0.042
Thrombosis level, n (%) 0.021
Renal vein 99/147 (67.3) 38/68 (55.9) 61/79 (77.2)
Subdiaphragmatic inferior vena cava 37/147 (25.2) 23/68 (33.8) 14/79 (17.7)
Supradiaphragmatic inferior vena cava/right atrium 11/147 (7.5) 7/68 (10.3) 4/79 (5.1)
Perirenal tissues invasion, n (%) 0.067
Absent 42/147 (28.6) 14/68 (20.6) 28/79 (35.4)
Present 105/147 (71.4) 54/68 (79.4) 51/79 (64.6)
Nodal status, n (%) 0.029
pN0/Nx 127/147 (86.4) 54/68 (79.4) 73/79 (92.4)
pN+ 20/147 (13.6) 14/68 (20.6) 6/79 (7.6)
Distant metastasis, n (%) 0.029
Absent 114/147 (77.6) 47/68 (69.1) 67/79 (84.8)
Present 33/147 (22.4) 21/68 (30.9) 12/79 (15.2)
Pathological grade, n (%) <0.001
2 10/129 (7.7) 1/52 (1.9) 9/77 (11.7)
3 58/129 (45.0) 16/52 (30.8) 42/77 (54.5)
4 61/129 (47.3) 35/52 (67.3) 26/77 (33.8)
Sarcomatoid differentiation, n (%) 1.000
Absent 121/147 (82.3) 56/68 (82.3) 65/79 (82.3)
Present 26/147 (17.7) 12/68 (17.7) 14/79 (17.7)
Microscopic necrosis, n (%) <0.001
Absent 54/147 (36.7) 12/68 (17.6) 42/79 (53.2)
Present 93/147 (63.3) 56/68 (82.4) 37/79 (46.8)
Microvascular invasion, n (%) 0.075
Absent 46/147 (31.3) 16/68 (23.5) 30/79 (38.0)
Present 101/147 (68.7) 52/68 (76.5) 49/79 (62.0)
P-value of the Fisher’s exact test (categorical variables) and of the Wilcoxon’s rank-sum test (numerical variables).
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distributions by the log–rank test did not show significant
differences (Fig. S1b,d). Similar results were found for OS
(Fig. S1a,c).
An extensive analysis showed that VTTC, when used to-
gether with other informative variables, did not significantly
improve the predictive value of two risk models for OS or
CSS. The prediction error curves of models with and without
VTTC, shown in Figure 2, are almost overlapping, and did not
show a significant contribution of this covariate to the prediction
of OS and CSS. This result was confirmed in Table S2, where
two measures of predictivity (Integrated Brier Score and time-
dependent area under the curve) and three reclassification mea-
sures (IDI, continuous-NRI and median improvement in risk
score) for models with/without VTTC were compared; no statis-
tically significant and clinically relevant differences were found.
Among patients with a fVTTC, the adjusted 5-year CSS in
patients with extensive and limited fVTTC was 50.3% (95%
CI 35.2–72.0%) and 64.2% (95% CI 45.8–90.0%), respec-
tively; the adjusted 5-year CSS for M0 patients with extensive
and limited fVTTC was 53.5% (95% CI 34.9–81.8%) and
87.1% (95% CI 71.9–100.0%), respectively. The comparison
of sVTTC to extensive and limited fVTTC did not show signif-
icant differences in CSS curves (Fig. S2b,d). Similar results
were found for OS (Fig. S2a,c).
Discussion
The present study reached four main findings. First, VTTC can
be reliably assessed, with a high interobserver agreement be-
tween an expert and a novice pathologist, confirming that the
diagnosis of this parameter is easy and reproducible.
Second, a fVTTC is indicative of an aggressive disease, be-
cause this pattern was strictly associated with some clinical
and pathological features that are typical of the more advanced
tumors – symptoms, lymphnodal and distant metastasis, larger
diameter, higher cephalad thrombosis level, necrosis and micro-
vascular invasion. This observation confirms what was reported
by the two previous studies on VTTC, with comparable cohorts
(147 vs 174 vs 184 patients) and median follow-up times (41 vs
24 vs 49 months).7,8 It could be speculated that the higher
clinical aggressiveness of fVTTC, shown by the association
with many adverse clinical factors, could be attributed to a
Table 2 Multivariable Cox regression analysis predicting OS and CSS in the overall cohort (n = 147) and in the M0 group (n = 114)
OS – all data
(M0 and M1) OS M0 group
CSS – all data
(M0 and M1) CSS M0 group
Variable HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (years)
Continuous variable 1.03 (1.00–1.06) 0.065 1.03 (0.99–1.08) 0.150 1.03 (1.00–1.06) 0.028 1.04 (0.99–1.08) 0.086
Thrombosis level
Subdiaphragmatic inferior vena
cava vs renal vein
2.37 (1.28–4.36) 0.006 3.41 (1.57–7.42) 0.002 2.39 (1.27–4.48) 0.006 3.73 (1.74–7.98) 0.001
Supradiaphragm. inferior vena
cava/right atrium vs renal vein
2.09 (0.75–5.83) 0.159 6.94 (2.00–24.08) 0.002 1.60 (0.59–4.30) 0.354 4.07 (1.25–13.27) 0.020
Perirenal tissues invasion
Present vs absent 3.21 (1.44–7.14) 0.004 4.42 (1.77–11.04) 0.001 2.36 (0.99–5.64) 0.053 3.68 (1.36–9.95) 0.010
Distant metastasis
Present vs absent 4.97 (2.62–9.43) <0.001 - - 3.51 (1.79–6.88) <0.001 - -
Pathologic grade
4 vs 2+3 3.02 (1.54–5.93) 0.001 1.95 (0.86–4.41) 0.108 2.68 (1.37–5.27) 0.004 1.63 (0.75–3.57) 0.220
Charlson Comorbidity Index, n (%)
1–2 vs 0 2.15 (1.11–4.20) 0.024 1.84 (0.78–4.35) 0.165 - - - -
≥3 vs 0 5.82 (1.77–19.17) 0.004 7.27 (2.03–25.99) 0.002 - - - -
Microvascular invasion
Present vs absent - - - - 1.93 (0.85–4.36) 0.115 2.68 (1.05–6.88) 0.040
Venous tumor thrombus consistency
Friable vs solid 1.03 (0.54–1.97) 0.921 1.68 (0.74–3.79) 0.212 0.92 (0.48–1.76) 0.804 1.55 (0.72–3.32) 0.262
Estimated survival
5-year survival (unadjusted)
Solid 72.7% (62.5% - 84.6%) 79.2% (69.2% - 90.5%) 74.9% (64.8% - 86.7%) 80.6% (70.8% - 91.8%)
Friable 47.0% (35.1% - 63.0%) 56.9% (42.7% - 75.8%) 51.4% (39.0% - 67.6%) 60.9% (46.6% - 79.7%)
5-year survival (adjusted)
Solid 59.0% (48.0% - 72.6%) 68.1% (56.8% - 81.7%) 61.0% (49.9% - 74.7%) 69.0% (57.7% - 82.5%)
Friable 57.0% (45.6% - 71.3%) 63.7% (50.0% - 81.0%) 60.6% (48.4% - 75.8%) 66.7% (53.0% - 83.9%)
10-year survival (unadjusted)
Solid 69.8% (58.8% - 82.8%) 75.9% (64.8% - 88.9%) 71.9% (60.9% - 84.9%) 77.3% (66.2% - 90.1%)
Friable 32.6% (21.0% - 50.5%) 40.6% (26,1% - 63.2%) 35.6% (23.3% - 54.6%) 43.5% (28.3% - 66.8%)
10-year survival (adjusted)
Solid 57.0% (45.6% - 71.3%) 65.7% (53.8% - 80.3%) 59.0% (47.4% - 73.5%) 66.6% (54.7% - 81.2%)
Friable 41.3% (28.9% - 59.2%) 46.8% (32.0% - 68.3%) 44.2% (31.1% - 62.8%) 49.0% (33.8% - 71.1%)
Unadjusted and adjusted estimated 5-year and 10-year survival with 95% confidence interval.
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greater tendency to the spreading of the tumor facilitated by a
lack of connective tissue and adhesion molecules that render less
cohesive cancer cells.8 In any case, the reliability and rapidity of
diagnosis, and the relationship with various other pathological
features make it advisable that VTTC should be reported by pa-
thologists, as it could contribute to the definition of the biology
of the disease, and indicate further investigations in cases with
friable VTTC and unexpected favorable morphological aspects.
Third, VTTC was not a statistically significant and clinically
relevant prognostic factor of survival when used together with
other pathological and clinical predictors. On one hand, the
univariate analysis showed that the presence of a fVTTC was
significantly associated with a worse OS and CSS survival, in
accordance with the two previous studies on VTTC.7,8 It is note-
worthy that the extension of the friable pattern (limited vs exten-
sive) has a relationship with survival, even if without statistical
significance. On the other hand, in contrast to previous studies,
the association between VTTC and survival was not confirmed
by multivariable analysis, and VTTC failed to significantly
improve the predictive ability of models that include other infor-
mative variables, such as the level of thrombosis, perirenal tissue
invasion, distant metastasis, high grading and Charlson index.
On this point, some criticisms can be made of the two previous
studies. Bertini et al. definitely stated that VTTC is a valuable in-
dependent prognostic factor, with respect to CSS and OS, in M0
and M1 cases; however, it should be noted that the additional
predictive value of VTTC that they estimated was statistically
significant, but of limited clinical value, being equal only to
+2.5%.7 Weiss et al. showed that VTTC is an adverse prognostic
predictor only for OS and solely in M0 patients, whereas CSS
was not assessed at all.8 It is also noteworthy that they did not
estimate any measure of predictivity for VTTC, and their
analysis of OS was not adjusted for comorbidities, which in
this setting are particularly relevant considering the age of
the patients and the morbidity of the surgical procedures.
Indeed, in our and in another study20 the Charlson index is
an independent predictor of OS. These data show that even
if fVTTC is indicative of unfavorable biological behavior, its
role in determining the prognosis is not relevant enough when
other stronger prognostic factors are considered. Obviously, it
cannot be excluded that in larger cohorts this effect could
become more evident.
Finally, we observed that all the cases with a papillary
subtype had a friable VTTC, and we suggested the hypoth-
esis that the growth pattern of this histological subtype,
typically with multiple papillae cannot be cohesive enough
to appear solid. Indeed, also in the study of Weiss et al.,
the papillary subtype had a fVTTC in 83% of cases,
confirming our observation.8 So, the chance that a thrombus
could be classified as solid in this histological subtype should
be better discussed, and VTTC should probably be reported
only for clear cell RCC.
Fig. 2 Prediction error curves for Cox and
RSF predictors with and without VTTC. (a)
OS in the whole dataset. (b) CSS in the whole
dataset. (c) OS in the M0 group. (d) CSS in the
M0 group.
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The main limitations of the present study were its retrospec-
tive design, limited sample size and the not negligible rate of
cases for whom slides were not available.
In conclusion, the present study showed that VTTC can
be reliably assessed, is strongly associated with several well-
established adverse prognostic factors, but does not indepen-
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